~ Updated, Long-term Results from the Phase I/II Dose-Escalating Study of AMT-060 to be Presented on Monday, July 10, 2017 ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two abstracts have been accepted for presentation at the International Society on Thrombosis and Hemostasis (ISTH) Congress held in Berlin, Germany, July 8 - 13, 2017. `The data to be featured in an oral presentation at ISTH now demonstrate long-term safety, efficacy and the potential for broad application of AAV5 in hemophilia B,`...
|